259 results on '"D'Souza, Deepak Cyril"'
Search Results
2. Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users
3. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
4. Preliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responses
5. The Acute Effects of Cannabinoids in Patients with Psychotic Illness
6. Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing
7. Dysregulation of the endogenous cannabinoid system following opioid exposure
8. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
9. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder
10. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial
11. Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)
12. Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controls
13. Going deep into schizophrenia with artificial intelligence
14. Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample
15. Psychedelics: Old trips, new destinations in psychopharmacology research
16. Editorial
17. Serotonergic Psychedelics – a Comparative review Comparing the Efficacy, Safety, Pharmacokinetics and Binding Profile of Serotonergic Psychedelics
18. Assessment of transient dopamine responses to smoked cannabis
19. Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis
20. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder
21. The Association Between Cannabinoids and Psychosis
22. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda
23. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis
24. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET
25. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J
26. The Psychosis-like Effects of Δ9-Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans
27. Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans
28. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial
29. Correction to: Psychedelics: Old trips, new destinations in psychopharmacology research
30. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J.
31. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects
32. Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophrenia
33. Revisiting the Consequences of Adolescent Cannabinoid Exposure Through the Lens of the Endocannabinoid System
34. Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information
35. Cannabis, cannabinoids and psychosis: a balanced view
36. The Association Between Cannabinoids and Psychosis
37. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
38. Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials
39. Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis
40. sj-docx-1-jop-10.1177_02698811231154852 – Supplemental material for Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
41. sj-docx-2-jop-10.1177_02698811231154852 – Supplemental material for Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
42. Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users
43. The early identification of psychosis: can lessons be learnt from cardiac stress testing?
44. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
45. Sex Differences in the Acute Effects of Intravenous (IV) Delta-9 Tetrahydrocannabinol (THC)
46. mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression
47. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
48. Presentation and Short-term Course of New Onset Cannabis Induced Psychotic Disorder in Males
49. Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”
50. TU85. POLYGENIC RISK SCORE FOR CANNABIS USE DISORDER PREDICTS ACUTE INTOXICATING EFFECTS AND COGNITIVE DEFICITS INDUCED BY DELTA-9-TETRAHYDROCANNABINOL: A PILOT STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.